Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel; Pertuzumab
- Indications Advanced breast cancer; Ductal carcinoma; Early breast cancer
- Focus Therapeutic Use
- 03 Aug 2017 Status changed from active, no longer recruiting to completed.
- 10 Nov 2016 Status changed from suspended to active, no longer recruiting.
- 29 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Apr 2017.